← Compound index
RESEARCH FAMILY / NT3-MIMETICS

NT-3 mimetics: GTS-301 & GTS-302ГТС-301 / ГТС-302

Two experimental peptides, GTS-301 and GTS-302, designed to mimic part of neurotrophin-3, a protein involved in nerve-cell signaling.

CognitionStress
Source linked

What the studies found

Animal research · 2026

Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke

GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.

Study notes · methods, sources and limitations

Participants or model Rats with middle cerebral artery occlusion

Important limitations

  • Animal experiment, not evidence of benefit in human stroke. Full methods, sample size and risk of bias require review. This is a separate stroke paper; the correction to an earlier NT-3 withdrawal study does not resolve or invalidate this paper automatically.

Pharmacokinetics and Pharmacodynamics. 2026;(1):12–19 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2022

The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.

GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.

Study notes · methods, sources and limitations

Participants or model Cell cultures and mice

Important limitations

  • Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.

Doklady. Biochemistry and biophysics · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2024

Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.

Study notes · methods, sources and limitations

Participants or model Morphine-dependent rats and HT-22 cells

Important limitations

  • Animal withdrawal models are not evidence for treating opioid dependence in people. The correction changes author spelling only; full experimental methods still require appraisal.

Biochemistry. Biokhimiia · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About NT-3 mimetics: GTS-301 & GTS-302

Names in this research collection

GTS-301 · GTS-302 · NT-3 · TrkC

Research background

A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
GTS-301Dimeric succinyl-Asn-Asn mimetic

Cell protection and mouse behavioral findings; later rat analgesia experiments are separate outcomes.

The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties. ↗

Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301. ↗

GTS-302Dimeric hydroxybutyryl-Glu-Asn mimetic

Rodent anxiety-, memory- and antidepressant-like tests; no hot-plate effect reported.

Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302. ↗

Direct comparisonTrkC/TrkB-related signaling

Different withdrawal and mechanical-pain responses in rats. The 2025 correction addresses author spelling only.

Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats. ↗

Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats. ↗

Interpretation and open questions

The withdrawal paper reports ERK/PLCγ signaling for GTS-301 and additional AKT/mTOR activation for GTS-302. These are experimental profiles, not treatment-selection rules.

The patent and subsequent papers may describe overlapping experiments. A 2026 stroke-comparison citation is cited, but its full text is unavailable here until the original report is checked.

Explore the Russian peptide research map ↗

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2023 · RU2800369C9 · Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9Molecule · Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures

Reported findings

GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.

Composite withdrawal index
Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposuresRelative to active control; nonmonotonic dose pattern retained
Neutral signs
No significant changes in general motor activity, rearing, grooming or several listed withdrawal signsNot every component improved
All reported results, comparisons and limitations →

Molecule. Corrected publication describing dimeric NT-3 peptide mimetics; proposed disease indications are not demonstrated human efficacy.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2800369C9 ↗ · 2023-10-04
Earliest priority / filing
Not established / 2022-04-05
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dimeric dipeptide mimetics of neurotrofin-3

Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Юлия Венеровна Вахитова; Полина Юрьевна Поварнина; Татьяна Алексеевна Антипова; Лариса Геннадьевна Колик; Нелля Михайловна Сазонова; Алексей Валерьевич Тарасюк; Дмитрий Михайлович Никифоров; Лиана Фанзилевна Зайнуллина; Марк Анатольевич Константинопольский; Светлана Сергеевна Ягубова; Рита Ушеровна Островская; Сергей Владимирович Николаев; Илья Олегович Логвинов.

RU2800369C9

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2026

Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke

GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.

Study notes and original source
2026Animal / experimentalEnglish abstract

Study of the neuroprotective effect of NT-3 dipeptide mimetics GTS-301 and GTS-302 on an experimental model of ischemic stroke

D. M. Nikiforov, P. Yu. Povarnina, T. A. Gudasheva · Pharmacokinetics and Pharmacodynamics. 2026;(1):12–19

GTS-302 reduced infarct volume by 39% and improved the day-three neurological measure; GTS-301 was inactive in this experiment.

Population / setting
Rats with middle cerebral artery occlusion
Source reviewed
Publisher-deposited abstract and metadata reviewed through Crossref; publisher website could not be retrieved.
Study limitations
  • Animal experiment, not evidence of benefit in human stroke.
  • Full methods, sample size and risk of bias require review.
  • This is a separate stroke paper; the correction to an earlier NT-3 withdrawal study does not resolve or invalidate this paper automatically.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2022

The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.

GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.

Study notes and original source
2022Animal / experimentalEnglish abstract

The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.

Gudasheva TA, Sazonova NM, Tarasiuk AV, Logvinov IO, Antipova TA, Nikiforov DM, Povarnina PY, Seredenin SB · Doklady. Biochemistry and biophysics

GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.

Population / setting
Cell cultures and mice
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2024

Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.

Study notes and original source
2024Animal / experimentalEnglish abstract

Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

Kolik LG, Konstantinopolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia

GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.

Population / setting
Morphine-dependent rats and HT-22 cells
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Animal withdrawal models are not evidence for treating opioid dependence in people.
  • The correction changes author spelling only; full experimental methods still require appraisal.

Reviewed 2026-10-05.

Read the source ↗

Research record · 2025

Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

The publisher corrects the second author’s surname to Mark A. Konstantinopolsky. The notice does not change experimental results and is not another experiment.

Study notes and original source
2025Study design unresolvedFull text available

Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

Kolik LG, Konstantinopolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia

The publisher corrects the second author’s surname to Mark A. Konstantinopolsky. The notice does not change experimental results and is not another experiment.

Population / setting
Correction notice
Source reviewed
Complete publisher correction text reviewed: author surname only. Original experimental paper remains abstract-reviewed.
Study limitations
  • Author-name correction only; it supplies no new efficacy or safety data.
  • Not an independent study or replication.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2025

Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.

GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.

Study notes and original source
2025Animal / experimentalEnglish abstract

Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.

Nikiforov DM, Povarnina PY, Gudasheva TA, Nadorova AV, Kolik LG, Valdman EA, Vakhitova YV, Seredenin SB · Doklady. Biochemistry and biophysics

GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.

Population / setting
Mice and rats
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2025

Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.

GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.

Study notes and original source
2025Animal / experimentalEnglish abstract

Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.

Kolik LG, Konstantinopolsky MA, Sazonova NM, Durnev AD, Gudasheva TA · Doklady. Biochemistry and biophysics

GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.

Population / setting
Rats; acute experimental pain testing
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Experiment described in a patent · 2023

Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9

The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.

Composite withdrawal index · Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures · Relative to active control; nonmonotonic dose pattern retained

Study notes and original source
2023Patent / reported experimentsRussian-language source

Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9

· Primary source linked above

The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.

Results and tables

Reported patent results

Reported findings

GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.

Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.

Population or model Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.

Results · Final withdrawal-model example; composite-index and unchanged-sign narrative.
MeasureResultComparison, timing and statistics
Composite withdrawal indexReported reductions of 26.9%, 41.4% and 36.5% across three tested exposuresRelative to active control; nonmonotonic dose pattern retained
Neutral signsNo significant changes in general motor activity, rearing, grooming or several listed withdrawal signsNot every component improved

Animal withdrawal scores do not establish treatment of human dependence. Values are specific to GTS-302 and cannot be assigned to all NT-3 mimetics.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Patent claims are not evidence of approved clinical uses.
  • Some publications describe shared experiments or have corrections.

Reviewed 2026-11-06.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗